Article metrics

Extended report
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

 

Online download statistics by month:

Online download statistics by month: August 2016 to October 2020

AbstractFullPdf
Aug 20161402930555
Sep 20161612966706
Oct 2016685603346
Nov 2016372576483
Dec 20161589378497
Jan 20171082507457
Feb 2017168374391
Mar 201739473292
Apr 201728524255
May 201712589273
Jun 2017181637279
Jul 2017486466207
Aug 2017456422192
Sep 2017481457197
Oct 2017472435251
Nov 2017576541221
Dec 2017698678244
Jan 2018676645219
Feb 2018611516215
Mar 2018604530173
Apr 2018481431143
May 2018605532183
Jun 2018442414191
Jul 2018402398162
Aug 2018397398141
Sep 2018444441177
Oct 2018639545214
Nov 2018613511180
Dec 2018498426127
Jan 2019566460194
Feb 2019422422138
Mar 2019458455161
Apr 2019369369136
May 2019447445141
Jun 2019388387159
Jul 2019347350279
Aug 2019336336382
Sep 2019401400382
Oct 2019422421346
Nov 2019387386245
Dec 2019302295199
Jan 2020348341242
Feb 2020298294211
Mar 2020345345203
Apr 2020317317172
May 2020321321147
Jun 2020308307148
Jul 2020311313172
Aug 2020272268107
Sep 202025824593
Oct 2020260254106
Total246342307412334